The CpGs in exon 2 of HLA-DRB1 that mediate the effect on MS risk belong to an intragenic CpG island that shows enrichment for binding sites of the ‘architectural’ regulatory protein of the genome CCCTC-binding factor (CTCF) (Table 1). This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.